derived sublines, resistant to increasing concentrations of Specific objectives of the group were (1) to record all the homoharringtonine (K562/HHT30, K562/HHT100, K562/ techniques used within the group; (2) to observe the range of HHT200, K562/HHT300, K562/HHT400), expressing increasvariation from one center to another when the same clinical ing levels of resistance to daunorubicin (DNR) (ϫ1.2, ϫ7, sample of leukemic cells was analyzed; (3) to try to under-ϫ30, ϫ125 and ϫ161) and increasing levels of MDR1/P-gp stand the reasons of potential discrepancies using cell lines expression evaluated by Northern blot, RT-PCR and immunoof known P-gp expression levels; (4) to suggest one standard staining by flow cytometry 5 were also sent blindly (in RPMI) protocol for each technique; and (5) to validate these sugto all the centers on three different occasions: K562, gested protocols on another set of cell lines and clinical K562/HHT100 and K562/HHT300 were sent twice, and all samples.
centers finally received the six cell lines for validation of the recommended techniques. Fresh samples were used for flow cytometry at 10 g/5 × 10 5 cells. In some instances, a higher concentration of MRK16 was used Cells from 12 patients with acute myeloid leukemia (10 AML de novo: eight before treatment, two after treatment failure, (50 g/5 × 10 5 cells) to check for antigen saturation. Rhodamine was recommended for functional tests (uptake and efflux and two myeloid blast crisis of chronic myelogenous leukemia), one patient with lymphoblastic leukemia (ALL ± modulator). 3rd step: Three cell lines expressing different levels of P-gp were sent twice blindly, in parallel with other Ph1+), and six chronic lymphoproliferative disorders (two chronic lymphocytic leukemias, three mantle cell lymphomas clinical samples. Two other antibodies (generously given) were compared to MRK16:4E3 (Centocor, Malvern, USA), with circulating lymphoma cells, one prolymphocytic leukemia) were separated by gradient density (Ficoll), washed, UIC2 (Immunotech). 4th step: Six cell lines with different levels of P-gp expression (including those already sent) were sent counted and sent as soon as possible to a variable number of centers (from eight to 35), depending on the quantity of availblindly, together with two clinical samples, with a complete guideline for flow cytometry immunophenotyping and able cells (Table 1 ). All the tested samples were from hyperleukocytosis patients (32 to 800 × 10 9 /l). To be analyzed, the uptake/efflux of rhodamine (see appendices 1 and 2), according to the consensus recommendations elaborated by the sample had to contain more than 90% viable cells (by trypan blue exclusion or propidium iodide staining).
Materials and Methods

Methods Cells
group at the end of step 3. 14 Seven measured uptake of an anthracycline PCR and MTT assay. 5, 21 Three centers participated only at the first step of the workshop: C Maugard-Louboutin (Centre René (daunorubicin in five cases, doxorubicin in one case, pirarubicin in one case) ± verapamil (5-50 M) (S9788 in one case), Gauducheau, Nantes, France) and L Danel-Moore (INSERM 391, Rennes, France), both using RT-PCR, and J Bénard five used rhodamine (rho) ± verapamil, two centers used uptake of both daunorubicin and rhodamine. Six centers also (Institut Gustave Roussy, Villejuif, France) using Northern blot.
tested dye efflux ± modulator. The results were expressed as percentage cells incorporating dye (one case) (compared to autofluorescence), as percentage modification of dye uptake Immunophenotyping by cytofluorometry (IP-CFM):
Eighteen centers used MRK16, at concentrations varying from 1 to (seven centers) or efflux (six centers) when modulator was added, or as the ratio of mean fluorescence dye + 50 g/5 × 10 5 cells, one center used 4E3 (10 g), one C219 (0.5 g). Goat anti-mouse MoAb labelled with FITC was used modulator/dye (one center). Concentrations of dye, type of uptake and time of efflux varied from center to center. as second antibody by all centers (except for the already labelled C219). A standard IgG was used as the control, and the results were expressed as a percentage of positive cells corrected from control staining, except in two centers: one
Results on first fresh leukemic cells: immunophenotyping with cytofluorometry (IP-CFM)
expressed the results as a ratio of fluorescence intensity of MoAb/control, 7 the other as the ratio of C219 fluorescence of sample/sensitive cell line P388. 16 The threshold for defining Samples handled without specific recommendations (Nos 1 to 10):
Only two centers did not use MRK16 for the first four 'positivity' varied from 5 to 20%, and was 1.5 when a ratio was chosen for expressing the results. Four centers tested samples. For all the other samples, aliquots of the same batch of MRK16 were sent to all centers (Table 2) . another MoAb together with MRK16: C219 in two centers, UIC2 in one, and JSB1 in one. A quantification of the number Two samples (Nos 1 and 5) were found homogeneously 'negative', but the number of centers receiving these samples of P-gp molecules was performed in one center (Biocytex, Marseille, France).
was low compared to the other samples (only six and eight centers, respectively). For the other eight cases, discordant results were observed between centers for IP-CFM, even in samples found negative with FT (No. 7) or with RT-PCR Immunocytochemistry (ICC):
Eight centers used ICC with (No. 9). These two samples showed large discrepancies K562/HHT100 and Ͼ10 6 for K562/HHT300. Finally, the six cell lines (K562 and K562/HHT30, 100, 200, 300 and 400) between centers for IP-CFM and ICC, raising the hypothesis of false-positive results due to a non-specific binding on the were sent again together with specific recommendations. The first level of recommendations was to use 10 g monocytic cells.
MRK16/5 × 10 5 cells; the second level was to use a complete protocol for cell preparation, the results having to be expressed as percentage of positive cells, with a threshold set Fixed samples analyzed by cytofluorometry (Nos 11 to 14) :
To analyze the role of the individual interpretation of at 1% (+) in the control; the third level was to recommend the same technique, viable cell gating after addition of propidium the data obtained by CFM in the differences observed, four samples were sent after staining with 10 g MRK16 or 10 g iodide, and to express the results as the ratio of the arithmetic mean of the fluorescence (FL1, linear values) for MRK16 to IgG2A (Becton Dickinson, Le Pont de Chay, France) and fixation with 3.5% paraformaldehyde (Figure 1) . Two cases were that of the control (see appendix 1). A threshold of 1.5 for this ratio was chosen as 'positivity' criterion. found negative in most centers (No. 11: 11% (+) ±9%, 2-28%; No. 13: 15% (+) ±15%, 2-57%), one case positive in most For all centers, K562/HHT300 was found repeatedly to be highly positive. For K562 and K562/HHT100, false positive centers (No. 12: 49% (+) ±31%, 6-90%), and one discordant (No. 14: 40% (+) ±26%, 1-78%). Large discrepancies were and false negative results (respectively) were observed, but this improved dramatically at the third step for IP-CFM as for observed for samples 12, 13 and 14. other techniques (Figure 3) , except for ICC.
Results obtained on K562 cell lines with different levels of P-gp expression:
The same cell lines were sent blindly three times ( 4 The cells lines, at the first and second step of recommendations ( Table 2 ). The data remained heterogeneous, with a majority used were fully characterized for MDR1 expression by Northern blot, RT-PCR, amount of P-gp and degree of resistance. 5 of negative results. Samples 18 and 19 were sent as tests after the final recommendations, and were mainly found negative, The first two dispatches were K562, K562/HHT100 and K562/HHT300. The number of sites for P-gp evaluated using except in one center for sample 19. This was in accordance with the RT-PCR and the majority of FT. Qifikit (Biocytex), 22 was 1000 for K562, 24 000 for
Figure 1
Percentage of positive cells in four samples sent after MRK16 staining. ND, not done. The extreme diversity K562/HHT100 cell line were tested with two concentrations of the tests used for FT could explain the discordance between of MRK16: 10 and 50 g/5 × 10 5 cells (Figure 4 ). An increase results: six samples were found to be mainly negative, correin the percentage of positive cells was noted in all cases, but sponding to the samples described as mainly negative with IPwas not dramatic except for the K562/HHT100 cell line, CFM ( Eighty-two samples were tested at 75%), and the heterogeneity of IP-CFM. The centers which 10 g/5 × 10 5 cells with both MRK16 and 4E3 antibodies by described these samples as 'positive' used uptake of DNR ± 13 centers. A very good correlation between the two antiverapamil (radioactive labelled DNR in one case, comparison bodies was observed by all centers (r 2 = 0.9).
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of mean fluorescence by cytofluorometry in one case), uptake of doxorubicin ± S9788 measured with cytofluorometry in one case, and efflux of rhodamine ± verapamil in one case. For MRK16 and UIC2:
Forty-four samples were tested by these three samples, the increase of dye uptake (or retention) seven centers with 10 g MRK16 and 1 g UIC2, according with modulator was borderline (+14 to 30%). to the manufacturer's recommendations. A good correlation was also noted by all centers (r 2 = 0.85).
Results obtained on K562 cell lines with different levels of Pgp expression:
When the K562 cell sublines were sent, the Expression of results for IP-CFM first step of recommendation was to use 0.1 M of rho ± 10 M verapamil; the second step was to use rho efflux ± verapamil; Results of 86 samples, tested with 10 g/5 × 10 5 cells, were the third level to use propidium iodide for gating the viable expressed as percentage of (+) cells and as ratio of arithmetic cells, and to express the results as a ratio of mean fluorescence mean fluorescence of MRK16/IgG2A by 10 centers. A positive (FL1) of rho + verapamil/rho, as for IP-CFM (Table 3 , Figure 2 ). correlation was found between both methods of expression This last approach permitted the elimination of false-posi-(r 2 = 0.8) (Figure 5 ). In cell lines, the ratio of MRK16/control tive results observed in the two first steps (2/7 and 2/13, fluorescence was more closely related to degree of resistance respectively) with the K562 parental cell line, and the rare than the percentage of positive cells (Figure 6 ).
false-negative result (1/7) observed at the first step of recommendation. The semi-quantification of dye efflux was more difficult to set, and minimum value of efflux for scoring (+)
Results of immunocytochemistry and (++) were not validated by the group: the ratio of mean fluorescence of rho + verapamil/rho was expressed as a conSeven centers used two or three anti P-gp antibodies to test 61 tinuous variable. samples. Discordant results between antibodies in the same centers occurred for 20 samples, precluding any conclusion in 33% of the cases. Because of a high background in negative controls, seven clinical samples were unevaluable. A total of
Results of other clinical samples 18, 19) : The discrepancies observed with samples 13, 14 and 15 reflected 27/61 (44%) samples could not be analyzed accurately by this technique. When cell lines were tested, MRK16 gave five out what was observed with IP-CFM and RT-PCR, despite the uniform use of 0.1 M of rho for the two first samples, and the of six expected results, JSB1 nine out of 12, and C219 five out of nine.
use of rho efflux for the third sample. Expression of rho efflux Comparison of results with two MRK16 concentrations (10 vs 50 g/10 6 cells).
Figure 2
Percentage of positive cells with MRK16 in three K562 sublines of different resistance levels. K562, K562/HHT100 and Discussion K562/HHT300 expressed respectively 1000, 24 000, and Ͼ10 6 P-gp sites.
The need for standardizing techniques of MDR phenotype measurement in clinical samples was documented by the workshop held in Memphis two years ago, and recently published. 3 The three samples of leukemia tested showed discrepancies among centers, and the results were also highly discordant for the myeloma cell line Dox1, expressing a low level ± modulator as a ratio of mean fluorescence was used for the last two samples: one was uniformously negative, but one of of P-gp, even with the highly sensitive technique of RT-PCR. In this study, the low number of participating centers using six centers found a (+) result for the last sample (efflux ratio: 2.1).
RT-PCR, IP-CFM and functional tests hampered the con-tribution, rendering the expression as percentage of 'positive cells' difficult. We confirm the importance of antibody concentration: at least 10 g/5 × 10 5 cells have to be used to clearly detect a low positive cell population. The use of 50 g/5 × 10
5 cells, as we tested in some samples, could be important for borderline values, but would be highly expensive. A solution could be the use of UIC2 or 4E3. In our hands, both antibodies, also recognizing external epitopes of P-gp, gave equivalent results to MRK16 and are less expensive. Schuurhuis et al 24 also found equivalent results between MRK16 and 4E3.
Expression of IP-CFM results, as a ratio of arithmetic mean of fluorescence for antibodies and for dye efflux (± modulator), suppressed the delicate choice of a threshold for positivity, and permitted a dramatic reduction in the difference between flow cytometry results. The set of a threshold for ratio at 1.5
Figure 5
Comparison between percentage of (+) cells and ratio of could be criticized, but corresponded to a significant differfluorescence using 10 g MRK16 in the 10 centers performing the ence, when the Kolmogorov-Smirnov (KS) test was used. The comparison.
inability of all centers to use this statistical test, and the good correlation observed between the ratio of fluorescence and the D value obtained with KS test (JY Perrot, unpublished data), argued for the use of a mean ratio, as in the two Dutch centers.
23
The difficulties of interpretation encountered by the centers performing ICC was also observed at the Memphis workshop: discordant results with ICC were given for the three AML samples tested, with only half and one third of the centers able to correctly detect P-gp for the intermediate and low level of P-gp, respectively. In our trial, all but one center used at least two antibodies, and cold acetone was the most used fixative. The use of a cut-off was not a problem, because the main discrepancies were between completely negative results with one antibody, and a high percentage of positive cells (often with low intensity) with another antibody. It appeared to the group that this method is not desirable, and we do not recommend it, even when two or three antibodies are used. This represents a major problem for the solid tumors, where cal upgrades are still needed at this level.
K0, K562; K1, K562/HHT30; K2, K562/HHT100; K3, K562/HHT200; K4, K562/HHT300; K5, K562/HHT400. clusions concerning these methods. On the other hand, ICC was largely tested, and was also shown to be not reproducible We thank J Antonini, C Cau, A Kataki, S Marchal, O Sabido, M Tabanazian for technical assistance, and Centocor, Immunin cells with low P-gp expression. The absence of repetitive blind tests after the consensus is frustrating, and decreases the otech and Valbiotech for P-gp antibodies. This work was supported by the 'Ligue Françaises contre le Cancer', the 'Fédér-value of the proposed recommendations. Broxterman et al 23 ran a bi-centric evaluation of different functional tests and ation Nationale des Centres de Lutte contre le Cancer', and a grant 'EMUL' 93201 from Assistance Publique-Hôpitaux de reported a good correlation between the two centers either for rhodamine or DNR uptake (± modulator), but the time to Paris. achieve this good correlation was not given. Determination of P-gp with IP-CFM followed the recommendations of the Memphis workshop, but no comparison between the two cenReferences ters was given. Our study is the largest multicentric evaluation 
